X4 Pharmaceuticals (NASDAQ: XFOR) insider transactions
In the twelve months to 10 November 2026, executives and directors of X4 Pharmaceuticals reported 5 open-market sales of 109,283 shares ($462,547) and 1 open-market purchase of 4,600 shares ($11,884), by 3 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 16 October 2026 | Craig Adam R | Executive Chairman | Open-market purchase | +4,600 | $2.58 | 333,251 | Form 4 |
| 1 October 2026 | Kirske David | Chief Financial Officer | Open-market sale | −11,767 | $2.86 | 155,983 | Form 4 |
| 12 August 2026 | Craig Adam R | Executive Chairman | Open-market sale | −47,436 | $4.44 | 328,651 | Form 4 |
| 12 August 2026 | Volpone John | President | Open-market sale | −24,576 | $4.44 | 265,305 | Form 4 |
| 30 June 2026 | Kirske David | Chief Financial Officer | Open-market sale | −8,543 | $4.26 | 167,750 | Form 4 |
| 12 May 2026 | Kirske David | Chief Financial Officer | Open-market sale | −16,961 | $4.29 | 176,293 | Form 4 |
| 23 October 2025 | Craig Adam R | Executive Chairman | Open-market purchase | +86,206 | $2.90 | 376,087 | Form 4 |
| 14 August 2025 | Kirske David | Chief Financial Officer | Grant or award | +193,254 | — | 193,254 | Form 4 |
| 14 August 2025 | Craig Adam R | Executive Chairman | Grant or award | +289,881 | — | 289,881 | Form 4 |
| 14 August 2025 | Volpone John | President | Grant or award | +289,881 | — | 289,881 | Form 4 |
| 9 June 2025 | Wyzga Michael S | Director | Grant or award | +1,500 | — | 5,555 | Form 4 |
| 9 June 2025 | McGirr David W J | Director | Grant or award | +1,500 | — | 4,722 | Form 4 |
| 9 June 2025 | Woods Keith | Director | Grant or award | +1,500 | — | 6,000 | Form 4 |
| 9 June 2025 | Bridger Gary | Director | Grant or award | +1,500 | — | 4,722 | Form 4 |
| 9 June 2025 | de Craecker Francoise | Director | Grant or award | +1,500 | — | 4,722 | Form 4 |
| 9 June 2025 | Stewart Murray | Director | Grant or award | +1,500 | — | 7,883 | Form 4 |
| 20 May 2025 | Thoren Natasha Fay | Chief Legal Officer | Grant or award | +3,333 | — | 9,462 | Form 4 |
| 16 May 2025 | Baldry Mark | Chief Commercial Officer | Open-market purchase | +1,032 | $2.48 | 25,337 | Form 4 |
| 12 February 2025 | DiBiase Mary | Chief Operating Officer | Grant or award | +650,000 | — | 1,140,980 | Form 4 |
| 12 February 2025 | Baldry Mark | Chief Commercial Officer | Grant or award | +600,000 | — | 729,173 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the X4 Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.